CRISPR Therapeutics (NasdaqGM:CRSP) recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction.
Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
Clinical Trials Arena on MSN20h
Epicrispr secures $68m for facioscapulohumeral muscular dystrophy therapy trialEpicrispr Biotechnologies has raised $68m in the initial close of its Series B financing round to commence the clinical trial ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback